Datar Cancer Genetics Announces break-through Innovative Ttreatment options for late-stage Cancer Patients
by Shrutee K/DNS
November 11, 2019: Datar Cancer Genetics Limited, a molecular genomics company
based in Nashik, Maharashtra, India, has announced outcomes of their
‘Resilient’ study, which offers new hope for late-stage cancer patients. The
study showed that in a majority of these patients (90.5%), further progression
of cancer was halted, while a significant number of patients (43%) responded to
the treatment, leading to a healthy decrease in the extent of their cancers.
The Trials
The trials, named RESILIENT, had patients with difficult cancers
receiving treatment guidance based on the Exacta solution analysis. Under this
trial, 143 patients started off being given the treatment, and 126 patients
were evaluable as per the study criteria. In these patients, cancer had
progressed following multiple treatment failures. All patients underwent PET-CT
and brain MRI scans prior to the start of the treatment. At the end of the
treatment too, they were made to undergo the same scans. In an encouraging
sign, while no treatment-related mortalities or critical adverse events were
reported in this study, a majority of these patients reported improvement in
the quality of their lives, said the ISO15189 and College of American
Pathologists (CAP)-accredited Company.
The unique approach adopted in the trial for determining the
drugs that can be effective for cancer patients has been made possible through
the Exacta analysis offered by Datar Cancer Genetics. It uses cutting-edge
technologies that analyse the DNA, RNA, proteins and circulatory tumour cells
of the patient. The Exacta analysis allows for the identification of critical
features of cancer. And based on the established efficacy and safety profile,
certain drugs or a combination of drugs thereof, are then indicated for
treatment. The solution involves comprehensive in-depth tumour gene expression
analysis, integration of millions of data points at the molecular level to
reveal all possible targets for precision drugs, which in turn enables
effective tumour burden monitoring, therapy response monitoring and detects
early therapy failure or recurrence.
Responses
Dr Tim Crook, Medical Oncologist at the St. Luke’s Cancer
Centre, Royal Surrey County Hospital, Guildford, UK, one of the authors of the
study, said, “Patients in the United Kingdom and all over the world have much
to gain from the outcome of this trial.”
According to Dr Vineet Datta, another of the authors, a unique
feature of this approach and innovative technology is the selection of the most
effective drug treatment combinations matched with drugs that offer the least
toxicity. “The conventional ‘Standard of Care’ approach does not take into consideration the overall genetic
architecture of a particular patient’s tumour, and consequently, the patient
could suffer from failed therapies or aggressive relapse. Difficult cancers do
not always need new treatments; rather an intelligent approach can yield
treatment benefits with existing anti-cancer drugs.”
Treatment
One of the most formidable challenges faced by the
cancer-treating community is to be able to achieve superior clinical outcomes
for refractory late-stage solid cancers among patients who have not responded
positively to multiple lines of clinical therapy. The reasons for this are
many. For one, some cancers become resistant to various types of drugs. And
once cancer turns drug-resistant, it poses serious clinical challenges,
including there being virtually no lines of treatment available to tackle it,
and the outcome moving towards palliative care.
In such a scenario, genetic tests serve diverse purposes,
including screening and diagnosis of genetic diseases, prediction of drug
responses and identifying targeted therapies to provide customized cancer care.
With the benefits of genetic testing increasingly getting established, it is
essential to make efforts to increase the level of access to genomic services
for all who can benefit from this late-stage condition.
Link of the study published: https://doi.org/10.18632/oncotarget.27188
Cancer in India
According to the Indian Council of Medical Research
(ICMR), India was home to 14 lakh cancer patients in 2016. And
this number is increasing year after year. Breast
cancer, cervical cancer, oral cancer, and lung cancer account for about 41 per
cent of the nation’s cancer burden. Of this, breast cancer is
the number one killer of women, and lung cancer the top killer of men in the
country.
About Datar Cancer Genetics
Datar Cancer Genetics Limited (DCGL) is a
molecular genetics facility established in 2013 as a Centre for Excellence in
precision genetic analysis with an aim to meet and exceed globally recognized
standards and to maximize customer satisfaction. DCGL is India’s most modern,
fully integrated facility for molecular pathology, genetic analysis &
tissue investigation, spread over more than 30000 sq. ft. It has focused largely on developing services that
offer a greater insight into precision, customized and personalized medicine
through its diverse ecosystem of innovative oncology solutions. It has a
strong and competent team of over 180,
comprising world-class scientists, researchers, specialist clinicians and data analysts
and a fully integrated sequencing, bio-informatics and interpretation
platforms, with access to international databases. DCGL is
accredited by the International Standards Organisation (ISO 9001, 2015),
National Accreditation Board for Laboratories (NABL) and the College of
American Pathologists (CAP). It offers its
solutions across 10 countries and in over 100 cities across India.
Comments
Post a Comment